.
CorriXR Therapeutics published preclinical data in Molecular Therapy Oncology demonstrating that CRISPR-directed editing of NRF2 restored chemosensitivity and reduced tumor growth in lung cancer models, with minimal off-target activity. Completed in collaboration with the Gene Editing Institute at ChristianaCare, this work supports CorriXR’s progress toward IND-enabling studies and potential clinical translation.
Read more here.